AI assistant
Immunovant, Inc. — Director's Dealing 2024
Dec 4, 2024
31436_dirs_2024-12-04_bfe82cff-eb8a-4d5b-93dc-68dd18aa5be3.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Immunovant, Inc. (IMVT)
CIK: 0001764013
Period of Report: 2024-12-02
Reporting Person: Hughes Douglas J. (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-12-02 | Common Stock | S | 5425 | $28.54 | Disposed | 119585 | Direct |
Footnotes
F1: The sale of shares of common stock reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 16, 2023 in order to satisfy applicable tax obligations arising in connection with the vesting and deferred settlement of a prior award of restricted stock units.
F2: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.05 - $28.99 per share, inclusive. The Reporting Person undertakes to provide
to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the
range set forth in this footnote to this Form 4.